Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A J Scheen

Showing results (361-370 of 595) with videos related to

Pageof 60
Sort By:
Revue Medicale De Liege|August 17, 2006
[Do statins have a place for cardiovascular prevention in elderly people?]J Petermans, J Laperche, A J Scheen
Revue Medicale De Liege|August 20, 2015
[STRENGTHS AND WEAKNESSES OF RANDOMISED CLINICAL TRIALS: EVOLVING CHANGES ACCORDING TO PERSONALIZED MEDICINE]Ph Ernest, B Jandrain, A J Scheen
Revue Medicale De Liege|December 5, 2008
[Benefit-risk ratio of coronary drug-eluting stents. 1st part: evaluation in the global population]A Nyssen, V Legrand, A J Scheen
Revue Medicale Suisse|October 7, 2011
[Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?]N Esser, N Paquot, A J Scheen
Revue Medicale De Liege|October 5, 2001
[Finapres, efficient technique in the assessment of orthostatic hypotension, autonomic neuropathy, and vaso-vagal syncope]A J Scheen, I Geronooz, M Marchand
Revue Medicale De Liege|July 23, 2005
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach]A J Scheen, L F Van Gaal
Revue Medicale De Liege|January 26, 2013
[How I explore ... a risk difference in the occurrence of an event in clinical trials]A J Scheen, P Ernest, B Jandrain
Revue Medicale De Liege|December 9, 2022
[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]A J Scheen, C Wallemacq, P Lancellotti
Revue Medicale De Liege|February 5, 2021
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management]P Lancellotti, A Ancion, A J Scheen
Revue Medicale De Liege|April 1, 2008
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Pageof 60

Showing results (361-370 of 595) with videos related to

Sort By:
Pageof 60
Revue Medicale De Liege|August 17, 2006
[Do statins have a place for cardiovascular prevention in elderly people?]J Petermans, J Laperche, A J Scheen
Revue Medicale De Liege|August 20, 2015
[STRENGTHS AND WEAKNESSES OF RANDOMISED CLINICAL TRIALS: EVOLVING CHANGES ACCORDING TO PERSONALIZED MEDICINE]Ph Ernest, B Jandrain, A J Scheen
Revue Medicale De Liege|December 5, 2008
[Benefit-risk ratio of coronary drug-eluting stents. 1st part: evaluation in the global population]A Nyssen, V Legrand, A J Scheen
Revue Medicale Suisse|October 7, 2011
[Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?]N Esser, N Paquot, A J Scheen
Revue Medicale De Liege|October 5, 2001
[Finapres, efficient technique in the assessment of orthostatic hypotension, autonomic neuropathy, and vaso-vagal syncope]A J Scheen, I Geronooz, M Marchand
Revue Medicale De Liege|July 23, 2005
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach]A J Scheen, L F Van Gaal
Revue Medicale De Liege|January 26, 2013
[How I explore ... a risk difference in the occurrence of an event in clinical trials]A J Scheen, P Ernest, B Jandrain
Revue Medicale De Liege|December 9, 2022
[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]A J Scheen, C Wallemacq, P Lancellotti
Revue Medicale De Liege|February 5, 2021
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management]P Lancellotti, A Ancion, A J Scheen
Revue Medicale De Liege|April 1, 2008
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Pageof 60